Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has entered into a definitive co-marketing and distribution agreement with S.T.U. GmbH. The Switzerland-based company manufactures and markets “Hemplix™” brand CBD oils. Per the terms of the agreement, Pivot’s proprietary cannabinoid-derived products will be marketed and sold by S.T.U. online and in retail stores, where regulations permit, in the U.K., Switzerland, Germany, Austria and Italy. Pivot will distribute the Hemplix™ product line where regulations permit, and upon receiving required licenses from regulatory authorities, in Canada, Latin America and the United States. “As we continue to execute on our business plan, Pivot has positioned itself to have the largest portfolio of bio-cannabis based health and wellness derivatives in the industry. To date, our team has secured a strong intellectual property portfolio; completed development of scientifically-based and patented product formulations; established manufacturing facilities in Canada and California; and solidified branding, marketing and distribution in major markets. Pivot is now well positioned to rapidly gain market share in the cannabis market resulting in significant revenue beginning in Q4 2018,” Pivot Pharmaceuticals CEO Dr. Patrick Frankham stated in the news release.
To view the full press release, visit http://nnw.fm/3dZ3S
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to Ready-To-Infuse Cannabis (“RTIC”) oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based products. For more information, visit the company’s website at www.PivotPharma.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]